Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Favezelimab/pembrolizumab - Merck Sharp & Dohme

Next Previous
X
Search
Drug Profile

Favezelimab/pembrolizumab - Merck Sharp & Dohme

Alternative Names: Coformulation favezelimab/pembrolizumab - Merck Sharp & Dohme; Mavezelimab/pembrolizumab - Merck Sharp & Dohme; MK 4280A; MK-4820A; Pembrolizumab/favezelimab - Merck Sharp & Dohme

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Hodgkin's disease
  • Phase II Bladder cancer; Endometrial cancer; Renal cell carcinoma; Small cell lung cancer; Squamous cell cancer
  • Phase I/II Malignant melanoma; Oesophageal cancer; Solid tumours

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Canada (IV, Infusion)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in China (IV, Infusion)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Germany (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top